Roche 454 FLX Sequencer

The Naval Medical Logistics Command intends to negotiate on a sole source basis (IAW FAR 13) with Roche Diagnostics Corporation, 9115 Hague Road, Indianapolis, IN 46256-1025, as the only source that can provide the needed Titanium reagent consumable supplies required to increase the high-throughput genomic sequencing capabilities using the 454 FLX sequencers in order to meet the requirements of a DTRA funded project. The innovative Titanium System that Roche has developed for its 454 sequencing platform improves upon the existing 454 FLX system allowing up to 100 million bases of sequencing data per run through upgrades of its FLX chemistry and major upgrades to the software. When the new Titanium reagent and consumables are used in combination with the Titanium instrument upgrade, a single instrument run results in five times more data. The kits required under this procurement action are: 5233526001, GS Titanium Sequencing Kit XLR70; 5233542001 GS Titanium LV emPCR Kit [Lib-L]; 5233658001 GS Titanium emPCR Breaking KitsLV; 5233674001 GS Titanium emPCR Filters SV 64pc; 5233682001 GS Titanium Pico Titer Plate Lit 70X75; and 5233747001 GS Titanium General Library Prep Kit. The reagents are manufactured especially for the Titanium upgraded instrument which is proprietary technology available only through Roche. This acquisition is being conducted under commercial acquisition procedures (IAW FAR 12). The intended procurement will be classified under North American Industry Classification System (NAICS) 325411. This notice of intent is not a request for competitive proposals and no solicitation document exists for this requirement. However, parties interested in responding to this notice will need to submit technical data sufficient to determine capability in providing the same product. All capability statements received within 10 days after publication of this synopsis will be considered by the Government. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Capability statements shall be submitted by email only as a MS Word or Adobe PDF attachment to Douglas Nathan at douglas.nathan@med.navy.mil. Statements are due by COB 19 December 2008. No phone calls accepted.